Gini Fleming to Interleukin-2
This is a "connection" page, showing publications Gini Fleming has written about Interleukin-2.
Connection Strength
0.070
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
Score: 0.051
-
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009 Sep; 117(1):83-9.
Score: 0.019